Jump to content

Novel cancer diagnosis

Recommended Posts

http://rdu.news14.com/content/headlines ... 57&SecID=2

Lung cancer is the leading cause of cancer death in the United States. Now, new research could help in early detection and treatment of the disease.

Only 14 percent of lung cancer patients make it to the five-year mark, so Chuck Waser knows he's lucky to be alive.

Chuck said, "It's been in some respects nothing short of a miracle."

After nearly two years of treatment Chuck is cancer- free.

What happens in this lab at Duke University offers promise to other lung cancer patients. Researchers can identify the difference between normal and cancerous lung tissue by comparing proteins.

Dr. Edward Patz Jr., thoracic radiologist at Duke University Medical Center said, "We hope by understanding the proteins in the cell, then we'll be able to understand why a cell acts a certain way. For instance, why a cell turns into a cancerous cell and what makes it a cancerous cell."

"So what this may allow us to do is to tailor therapy based on what exact type of tumor someone has," said Dr. Michael Campa, radiology researcher.

Chuck beat the odds and hopes this new research gives other patients that same chance.

Chuck said, "Certainly the earlier you catch it, the better chance you have of getting remission or effectively getting a cure."

While lung cancer is the model currently being tested at Duke, researchers say the new technology could be applied to other types of cancers and diseases as well.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use.